ADCs engineered to overcome
cancer’s toughest challenges
Learn more about how Byondis is engineering antibody-drug conjugates (ADCs) to tackle the cancers that current therapies cannot reach
Get to know us
Swipe
Pipeline - Promising, novel, wholly-owned ADC technology platforms
The challenge that drives us
Despite remarkable advances in oncology research and therapeutics, many cancers remain intractable. Too many patients are unable to benefit from existing treatments, facing harsh side effects without achieving a durable response, especially in difficult-to-treat settings. 5Spaceraddexpandmore-dots Spacing (px)
The challenge is clear. We must eliminate the impossible trade-off between efficacy and safety. While ADCs hold tremendous promise as precision cancer therapies, their full potential remains unrealized. Smarter, more precise ADC therapies are needed to expand treatment options, overcome resistance, and restore hope for patients facing cancer’s toughest challenges.
Enabling ADCs to fulfill their therapeutic potential
Byondis is at the forefront of antibody-drug conjugate (ADC) innovation. Byondis is evolving the field with novel payload platforms, advanced masking technology, and optimized linker and conjugation strategies, enabling the development of ADCs with superior efficacy, duration of response, and safety to improve clinical outcomes and bring hope to patients.
Our modular platforms can be combined to address multiple hallmarks of cancer, creating differentiated ADCs engineered to outperform current therapies and tackle difficult-to-treat tumor types. Through our proprietary technology portfolio, including first-in-class antifolate and immunostimulatory phosphonate payloads, and best-in-class universal masking technology, we’re moving beyond the limitations of today’s ADCs to expand treatment options and restore hope for patients facing cancer’s toughest challenges.
Flexible platform approach with integrated capability
Byondis’ modular approach to ADC design enables partnering flexibility through co-development, licensing, and strategic collaboration.
Operating from state-of-the-art facilities in Nijmegen, the Netherlands, our end-to-end capabilities, spanning pre-clinical and clinical R&D, GMP manufacturing, and regulatory engagement, enable efficient development from discovery through to commercial launch. We establish strategic collaborations, licensing opportunities, and co-development partnerships across our platforms and proprietary programs.
